Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 26;20(11):108.
doi: 10.1007/s11886-018-1063-y.

Dangers of Overly Aggressive Blood Pressure Control

Affiliations
Review

Dangers of Overly Aggressive Blood Pressure Control

Faisal Rahman et al. Curr Cardiol Rep. .

Abstract

Purpose of review: Recent US guidelines have changed the definition of hypertension to ≥ 130/80 mmHg and recommended more intense blood pressure (BP) targets. We summarize the evidence for intense BP treatment and discuss risks that must be considered when choosing treatment goals for individual patients.

Recent findings: The SPRINT study reported that treating to a systolic BP target of 120 mmHg reduces cardiovascular outcomes in high-risk individuals, supporting more intensive BP reduction than previously recommended. However, recent observational studies have placed emphasis on the BP J-curve phenomenon, where low BPs are associated with adverse cardiovascular outcomes, suggesting that overly aggressive BP targets may sometimes be harmful. We attempt to reconcile these apparent contradictions for the clinician. We also review other potential dangers of aggressive BP targets, including syncope, renal impairment, polypharmacy, drug interactions, subjective drug side-effects, and non-adherence. We suggest a personalized approach to BP drug management considering individual risks, benefits, and preferences when choosing therapeutic targets, recognizing that a goal of 130/80 mmHg should always be considered. Additionally, we recommend an intense focus on lifestyle changes and medication adherence.

Keywords: Blood pressure; Cardiovascular disease; Hypertension; Polypharmacy; Risks.

PubMed Disclaimer

References

    1. JAMA Intern Med. 2014 Apr;174(4):588-95 - PubMed
    1. Circulation. 2018 Jan 9;137(2):134-143 - PubMed
    1. Hypertens Res. 2011 Jan;34(1):87-90 - PubMed
    1. Lancet. 1997 Sep 13;350(9080):757-64 - PubMed
    1. N Engl J Med. 2010 Apr 29;362(17):1575-85 - PubMed

MeSH terms

Substances

LinkOut - more resources